Pediatric Exclusivity Granted on Risperdal
Posted on: Thursday, 1 March 2007, 15:01 CST
U.S. firm Janssen said Thursday it has won six months' pediatric market exclusivity for doing pediatric studies of Risperdal.
The patent on the drug -- indicated for bipolar 1 disorder and schizophrenia in adults -- was set to expire in December, but the pediatric exclusivity extends the patent through June 2008, the company said.
Last October the Food and Drug Administration approved expanded labeling for the anti-psychotic drug for the treatment of irritability associated with autistic disorder, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods, in children and adolescents ages 5 to 16 years.
The new indication marks the first time the FDA has approved any drug for use in autistic children and adolescents, Janssen said.
Source: United Press International
Related Articles
- This Essential Report on Pediatric Drug Delivery Is Now Available
- Ped Med: Pediatric Drug Costs Soaring
- Pediatric Study Costs Rose Substantially From 2000 As Complexity Grew, According to Tufts Center for the Study of Drug Development
- MAP Pharmaceuticals Reports Positive Phase 2 Results for Its Pediatric Asthma Drug Candidate
- Sanofi-Aventis Allergy Drug Approved for Pediatric Use
- Generic Pediatric AIDS Drug Gets U.S. OK
- First Horizon Receives FDA Orphan Drug Designation for Its Glycopyrrolate to Treat Chronic Drooling in Pediatric Patients
- Pediatric Drug Delivery No Longer an Afterthought
- Shortages of Pediatric Cancer Drugs Are Common
- U.S. Pediatric Studies Have Led to New Labeling for Nearly 100 Drugs
 |
 |
User Comments (0)
RSS Feeds